An Introduction to Glaucoma
Numerous updates in the glaucoma treatment landscape have had a big impact on patient outcomes. The introduction of minimally invasive glaucoma surgeries (MIGS) and the approval of new drugs with new mechanisms of action, for the first time in decades, have transformed the landscape. Ongoing research into new drug delivery systems is likely to provide more effective and convenient treatments in the future.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Bryan Ang, AAO 2021: Gel Stent for Open Angle Glaucoma
It was wonderful to catch up with Bryan Ang (Tan Tock Seng Hospital, Novena, Singapore) about the Xen®45 (Allergan Inc., Irvine, CA, USA) and its use in treating open angle glaucoma. Questions: What factors can cause failure of minimally invasive glaucoma surgery (MIGS)? (00:15) When should bleb needling be considered during MIGS with the Xen45 […]
Micro-pulse Transscleral Laser Therapy and ‘Topical-plus’ Anaesthesia: Ideal for Glaucoma Management During COVID-19
touchREVIEWS in Ophthalmology. 2021;15(2):50-54
Continuous-wave transscleral laser cyclophotocoagulation (CW-TSCPC) is a well-established procedure in the surgical armamentarium of glaucoma management.1 It offers a non-incisional option in the treatment of end-stage refractory glaucoma, in which fistulating surgery and maximum tolerated medical therapy have failed to achieve a target intraocular pressure (IOP).2 CW-TSCPC is typically delivered using the G-Probe® (IRIDEX Corporation, Mountain View, […]
Sarah Van Tassel, Kiaweh Eye 2021: Challenges and Benefits of Drug Delivery Devices in Glaucoma
We were delighted to catch up with Sarah Van Tassel (Weill Cornell Medicine, NY, USA), who shared her observations on the challenges and benefits of drug delivery devices in glaucoma, the intraocular devices currently on the market and what to watch out for in future. What are the challenges and benefits of drug delivery […]
Sarah Van Tassel, Kiaweh Eye 2021: New Drugs and Drug Delivery Options for Glaucoma Management
It was a pleasure to speak with Sarah Van Tassel (Weill Cornell Medicine, NY, USA) on her thoughts about the new therapeutic options for glaucoma management and the promising new combinations on the horizon. How has the pharmaceutical landscape for glaucoma developed in the last year? (00:12) Where do rho-kinase inhibitors sit in the treatment […]
Thomas V Johnson, AGS 2021: Current Status and Future Challenges of Stem Cell-based Retinal Ganglion Cell Transplantation in Glaucoma Therapy
We were delighted to speak with Dr Thomas V Johnson (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA) and find out his thoughts on the current status and future challenges of stem cell-based retinal ganglion cell transplantation in glaucoma therapy, and the challenges and opportunities of the online format of this year’s virtual meeting. […]
Thomas V Johnson, AGS 2021: Cell Intrinsic and Microenvironmental Modulators of Human Stem Cell Derived RGC Survival and Retinal Integration Following Transplantation
It was a pleasure to speak to Dr Thomas V Johnson (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA) about his presentation at AGS 2021, investigating cell intrinsic and microenvironmental modulators of retinal ganglion cell survival and retinal integration following transplantation. Questions What were the aims and design of your study investigating cell intrinsic […]
Qi Cui, AGS 2021: Promising Novel Therapies in Glaucoma and Meeting Highlights
It was great to speak with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA) about her views on the most promising novel therapies targeting risk factors other than intraocular pressure in glaucoma, and her highlights from AGS21. Questions What are the most promising novel therapies targeting risk factors other than intraocular pressure […]
Qi Cui, AGS 2021: The GLP-1R Agonist NLY01 Reduces Neuroinflammation and Protects against RGC Loss in a Preclinical Glaucoma Model
We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development. Questions What is NLY01 and what is the rationale for its use in glaucoma therapy? (00:20) Could you give […]
David Huang, AGS 2021: Predictive Value of Baseline Visual Field, Disc, and Optical Coherence Tomography Diagnoses on Subsequent Glaucoma Progression
It was a pleasure to speak with Prof. David Huang (OHSU Casey Eye Institute, Portland, OR, USA) about his presentation at AGS 2021 on the predictive value of baseline visual field, disc and optical coherence tomography diagnoses on subsequent glaucoma progression. Questions Prior to your study, what was already known about the ability of baseline […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!